
On Monday, Ohio Attorney General Dave Yost sued six corporate entities over how they facilitate drug transactions. Yost filed the suit under the Valentine Act — Ohio’s antitrust law — accusing the companies of improperly colluding to fix prices and other actions regarding prescription drugs.
The main target of the lawsuit is St. Louis-based Express Scripts. It’s one of the three biggest drug middlemen in the United States.
Related: US: DOJ Oks Cigna/Express Scripts $52b merger
The three “pharmacy benefit managers” have a significant market share where they negotiate rebates with manufacturers and determine reimbursements to pharmacies while reconciling transactions at the drug counter.
Also being sued are Express Scripts’ corporate parents, Cigna and Evernorth, and Ascent Health Services, a “group purchasing organization” it started in 2019. In addition, the suit names as defendants Prime Therapeutics — a smaller PBM owned by Blue Cross and Blue Shield which co-owns Ascent — as well as Humana Pharmacy Solutions, an Ascent customer.
Featured News
Australia’s Major Supermarkets Face Scrutiny Over Profit Margins Amid Rising Prices
Mar 21, 2025 by
CPI
Fired FTC Commissioners Warn of Potential White House Influence Over Mergers
Mar 20, 2025 by
CPI
Dr. Matthew Backus Joins Compass Lexecon as an Affiliate
Mar 20, 2025 by
CPI
UK to Boost Broadband Competition While Capping Openreach Charges, Says Ofcom
Mar 20, 2025 by
CPI
Singapore Competition Watchdog Yet to Receive Formal Notification on Grab-GoTo Merger
Mar 20, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Self-Preferencing
Feb 26, 2025 by
CPI
Platform Self-Preferencing: Focusing the Policy Debate
Feb 26, 2025 by
Michael Katz
Weaponized Opacity: Self-Preferencing in Digital Audience Measurement
Feb 26, 2025 by
Thomas Hoppner & Philipp Westerhoff
Self-Preferencing: An Economic Literature-Based Assessment Advocating a Case-By-Case Approach and Compliance Requirements
Feb 26, 2025 by
Patrice Bougette & Frederic Marty
Self-Preferencing in Adjacent Markets
Feb 26, 2025 by
Muxin Li